151 material Form 8-K filings that 136 companies we cover made with the SEC in February 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Chemed reported fourth-quarter 2023 revenue of $585.9 million, up 7.2%, with GAAP diluted EPS of $5.90, up 42.9%, and adjusted diluted EPS of $6.60, up 35.0%. The company gave 2024 adjusted diluted EPS guidance of $23.30 to $23.70, compared with $20.30 in 2023, while Roto-Rooter revenue fell 1.1% in the quarter.
Q4 2023 revenue rose 7.2% to $585.9 million; GAAP diluted EPS was $5.90 and adjusted diluted EPS was $6.60
VITAS net patient revenue rose 13.6% to $350.0 million; Roto-Rooter revenue fell 1.1% to $235.9 million
2024 guidance: adjusted diluted EPS of $23.30 to $23.70 versus $20.30 adjusted EPS in 2023
As of December 31, 2023, cash and cash equivalents were $264.0 million with no current or long-term debt
Protagonist Therapeutics reported fourth-quarter 2023 net income of $27.3 million, or $0.44 per diluted share, compared with a net loss of $34.2 million in the same quarter of 2022. Revenue came from $60 million in JNJ-2113 milestones, while the full-year net loss narrowed to $79.0 million from $127.4 million.
Q4 2023 license and collaboration revenue was $60 million, versus zero in Q4 2022, from milestones tied to JNJ-2113.
Full-year 2023 net loss was $79.0 million, or $1.39 per share, compared with $127.4 million, or $2.60 per share, in 2022.
Cash, cash equivalents and marketable securities were $341.6 million as of December 31, 2023, up from $237.4 million a year earlier.
Republic Services reported fourth-quarter 2023 net income of $439.6 million, or $1.39 per diluted share, up from $1.09 a year earlier, on revenue of $3,831.6 million, up 8.6 percent. For 2024 it expects adjusted diluted EPS of $5.94 to $6.00, compared with adjusted EPS of $5.61 for 2023, and revenue of $16.100 billion to $16.200 billion.
Q4 2023 revenue was $3,831.6 million, up 8.6 percent, including 2.9 percent growth from acquisitions.
Q4 2023 adjusted EPS was $1.41, up from $1.13; full-year 2023 adjusted EPS was $5.61, up from $4.93.
2024 guidance: adjusted EBITDA of $4.825 billion to $4.875 billion and adjusted free cash flow of $2.100 billion to $2.150 billion.
Quarterly dividend of $0.535 per share is payable April 15, 2024, to holders of record on April 2, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.